Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04698252 | Local Therapy for ER/PR-positive Oligometastatic Breast Cancer(LARA) | recruiting | Phase 2 | 74 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT04914026 | MicroRNA as Markers in Testicular Cancer | recruiting | — | 350 | Haukeland University HospitalOTHER | 2 | Aug 8, 2022 | clinicaltrials |
| NCT05491395 | Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction(PROMART) | recruiting | N/A | 120 | Barretos Cancer HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT04985032 | Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) | recruiting | — | 200 | RPCR, Inc.OTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT04681469 | Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC(PRIME) | recruiting | Phase 2 | 49 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05434026 | Chinese Colorectal Cancer Database(CCCD) | recruiting | — | 200,000 | Beijing Friendship HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05366478 | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05025813 | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma(DESQUAMATE) | recruiting | Phase 2 | 27 | Queensland HealthOTHER_GOV | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05300269 | SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | recruiting | Phase 2 | 73 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04520074 | Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | recruiting | Phase 3 | 590 | Fudan UniversityOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05469022 | Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy | recruiting | Phase 2 | 40 | Konkuk University Medical CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05466565 | Antiviral Therapy for Patients With Liver Cancer After Surgery | recruiting | — | 360 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05467189 | Antineoplastic Drugs in Elderly Patients | recruiting | — | 500 | Shandong UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05320588 | A Study in Patients With Advanced Cancers | recruiting | Phase 1 / Phase 2 | 332 | BiOneCure Therapeutics Inc.INDUSTRY | 1 | Jul 19, 2022 | clinicaltrials |
| NCT05415631 | Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence(Bladder-PAD) | recruiting | — | 500 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05305092 | Assessment of Brain Cognitive Impairment in Breast Cancer | recruiting | — | 90 | Tang-Du HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05447169 | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | recruiting | — | 11,625 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05227534 | Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)(PREVENT) | recruiting | N/A | 12,500 | Guangzhou Burning Rock Dx Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05392413 | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | recruiting | — | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445011 | Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445154 | SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05352321 | Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma | recruiting | N/A | 264 | Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05420454 | A Study for the Neoadjuvant Treatment of Breast Cancer | recruiting | Phase 4 | 1,576 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05420467 | A Study for the Adjuvant Treatment of Breast Cancer | recruiting | Phase 4 | 2,413 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05431257 | Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling(LD-VenEx) | recruiting | Phase 2 | 117 | Rigshospitalet, DenmarkOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05426135 | Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment | recruiting | — | 3,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04951635 | A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer | recruiting | Phase 3 | 150 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT04595019 | Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer(HERMES) | recruiting | N/A | 46 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT05341141 | Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy | recruiting | N/A | 102 | Peking UniversityOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT04499833 | HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma(HepatoPredict) | recruiting | N/A | 40 | Centro Hospitalar de Lisboa CentralOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03829553 | Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment(HARVEST) | recruiting | Phase 3 | 801 | Ruijin HospitalOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05395962 | Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer(Elechtra) | recruiting | Phase 2 | 92 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 82 | AbClonINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT04079049 | BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases(BreCLIM-2) | recruiting | Phase 3 | 200 | Umeå UniversityOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05375591 | AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer(AI-SONAR) | recruiting | — | 1,000 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05373810 | Registration Study Sarcoma | recruiting | — | 1,000 | Radboud University Medical CenterOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT04306458 | RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).(ROBOT-2) | recruiting | N/A | 218 | University Medical Center MainzOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05182944 | A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC | recruiting | Phase 2 | 130 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT04437329 | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 352 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05367206 | Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial(N6C) | recruiting | Phase 3 | 280 | Sun Yat-sen UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04708171 | The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections(PROGRAM) | recruiting | — | 453 | Erasmus Medical CenterOTHER | 5 | May 6, 2022 | clinicaltrials |
| NCT05363657 | International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors(i-RECORd) | recruiting | — | 10,000 | Azienda Ospedaliero-Universitaria CareggiOTHER | 13 | May 6, 2022 | clinicaltrials |
| NCT03972956 | Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease | recruiting | — | 1,000 | Renmin Hospital of Wuhan UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05141253 | Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | recruiting | Early Phase 1 | 24 | Tongji HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 8, 2022source: clinicaltrials